Recombinant Human Siglec-5 / CD170 Protein, Fc Tag, 200 µg

Background
Sialic acid-binding Ig-like lectin 5 (SIGLEC5) is also known as CD33 antigen-like 2 (CD33L2), Obesity-binding protein 2 (OB-BP2), CD antigen CD170, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. SIGLEC5 / CD170 is expressed by monocytic / myeloid lineage cells. SIGLEC-5 / CD33-L2 binds equally to alpha-2,3-linked and alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.

Source
Recombinant Human SIGLEC5 /OB-BP2 /CD170 Protein, Fc Tag (SI5-H5250) is expressed from human 293 cells (HEK293). It contains AA Glu 17 - Thr 434 (Accession # AAH29896).
Predicted N-terminus: Glu 17

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 73.0 kDa. The protein migrates as 90-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Pretreatment soluble Siglec-5 protein predicts early progression and R-CHOP efficacy in diffuse large B-cell lymphoma"
Sun, Cao, Sun et al
Biomark Med (2023) 17 (3), 143-158
(2) "Carbon nanotube recognition by human Siglec-14 provokes inflammation"
Yamaguchi, Xie, Ito et al
Nat Nanotechnol (2023)
(3) "Tamoxifen Modulates the Immune Landscape of the Tumour Microenvironment: The Paired Siglec-5/14 Checkpoint in Anti-Tumour Immunity in an In Vitro Model of Breast Cancer"
Wielgat, Rogowski, Czarnomysy et al
Int J Mol Sci (2023) 24 (6)
Showing 1-3 of 95 papers.